50 million euros for gene therapy
Amsterdam – At the end of June, gene therapy specialist Amsterdam Molecular Therapies NV (AMT) raised a50 million in an IPO and private placement at Euronext. The price was at the top of the proposed a8 to a10 bookbuilding range, valuing the company at a139.3 million. AMT’s lead compound is AMT-011, an adeno-associated virus gene therapy that has completed Phase I/II testing for the treatment of type I and type V lipoprotein lipase deficiency. LPL deficiency in humans is a debilitating disease that is associated with extremely high serum triglyceride concentrations, a high morbidity and increased mortality.